{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:44:10Z","timestamp":1793727850618,"version":"4.6.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270682"],"award-info":[{"award-number":["82270682"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LQ21H030007"],"award-info":[{"award-number":["LQ21H030007"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LQ20H30006"],"award-info":[{"award-number":["LQ20H30006"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hepatobiliary & Pancreatic Diseases International"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.hbpd.2024.11.004","type":"journal-article","created":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T02:14:23Z","timestamp":1731723263000},"page":"157-163","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Systemic chemotherapy improves outcome of hepatocellular carcinoma patients treated with transarterial chemoembolization"],"prefix":"10.1016","volume":"24","author":[{"given":"Wei-Chen","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke-Yi","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song-Feng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-E","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-Xi","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Yan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Fang","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin-Ping","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hbpd.2024.11.004_bib0001","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.hbpd.2024.11.004_bib0002","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S0168-8278(02)00360-4","article-title":"Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy","volume":"38","author":"Imamura","year":"2003","journal-title":"J Hepatol"},{"key":"10.1016\/j.hbpd.2024.11.004_bib0003","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1002\/hep4.1923","article-title":"Global and regional long-term survival following resection for HCC in the recent decade: a meta-analysis of 110 studies","volume":"6","author":"Reveron-Thornton","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.hbpd.2024.11.004_bib0004","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1097\/SLA.0000000000003358","article-title":"Surgery for recurrent hepatocellular carcinoma: achieving long-term survival","volume":"273","author":"Yoh","year":"2021","journal-title":"Ann Surg"},{"key":"10.1016\/j.hbpd.2024.11.004_bib0005","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.jhep.2020.09.026","article-title":"Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: a randomized phase III trial","volume":"74","author":"Kim","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.hbpd.2024.11.004_bib0006","doi-asserted-by":"crossref","first-page":"e14498","DOI":"10.1097\/MD.0000000000014498","article-title":"Systematic review of treatment strategy for recurrent hepatocellular carcinoma: salvage liver transplantation or curative locoregional therapy","volume":"98","author":"Wang","year":"2019","journal-title":"Medicine"},{"key":"10.1016\/j.hbpd.2024.11.004_bib0007","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jhep.2020.03.005","article-title":"Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma","volume":"73","author":"Kim","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.hbpd.2024.11.004_bib0008","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1200\/JCO.2015.61.4925","article-title":"Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma","volume":"34","author":"Wahl","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hbpd.2024.11.004_bib0009","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.hbpd.2024.11.004_bib0010","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1159\/000509424","article-title":"Guidelines for the diagnosis and treatment of hepatocellular carcinoma","volume":"9","author":"Zhou","year":"2020","journal-title":"Liver Cancer"},{"key":"10.1016\/j.hbpd.2024.11.004_bib0011","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1200\/JCO.20.00808","article-title":"Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma","volume":"38","author":"Finn","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hbpd.2024.11.004_bib0012","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hbpd.2024.11.004_bib0013","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1159\/000514313","article-title":"Downstaging and resection of initially unresectable hepatocellular carcinoma with tyrosine kinase inhibitor and anti-PD-1 antibody combinations","volume":"10","author":"Zhu","year":"2021","journal-title":"Liver Cancer"},{"key":"10.1016\/j.hbpd.2024.11.004_bib0014","doi-asserted-by":"crossref","first-page":"227","DOI":"10.21037\/hbsn-21-328","article-title":"Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition)","volume":"11","author":"Sun","year":"2022","journal-title":"Hepatobiliary Surg Nutr"},{"key":"10.1016\/j.hbpd.2024.11.004_bib0015","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/s41571-023-00746-1","article-title":"Neoadjuvant therapy for pancreatic cancer","volume":"20","author":"Springfeld","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.hbpd.2024.11.004_bib0016","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1200\/JCO.20.03399","article-title":"Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline","volume":"39","author":"Korde","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hbpd.2024.11.004_bib0017","doi-asserted-by":"crossref","first-page":"847","DOI":"10.21037\/jgo-20-220","article-title":"Neoadjuvant therapy in locally advanced colon cancer: a meta-analysis and systematic review","volume":"11","author":"Cheong","year":"2020","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.hbpd.2024.11.004_bib0018","doi-asserted-by":"crossref","first-page":"242","DOI":"10.3346\/jkms.2009.24.2.242","article-title":"The efficacy of hepatic resection after neoadjuvant transarterial chemoembolization (TACE) and radiation therapy in hepatocellular carcinoma greater than 5 cm in size","volume":"24","author":"Choi","year":"2009","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.hbpd.2024.11.004_bib0019","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1097\/SLA.0b013e31818a07d4","article-title":"Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation","volume":"248","author":"Chapman","year":"2008","journal-title":"Ann Surg"},{"key":"10.1016\/j.hbpd.2024.11.004_bib0020","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jhep.2015.01.023","article-title":"Does pathological response after transarterial chemoembolization for hepatocellular carcinoma in cirrhotic patients with cirrhosis predict outcome after liver resection or transplantation?","volume":"63","author":"Allard","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.hbpd.2024.11.004_bib0021","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.hbpd.2022.07.007","article-title":"The effect of adjuvant transarterial chemoembolization for hepatocellular carcinoma after liver resection based on risk stratification","volume":"22","author":"Zeng","year":"2023","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"10.1016\/j.hbpd.2024.11.004_bib0022","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/S1470-2045(24)00457-1","article-title":"Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis","volume":"25","author":"D'Alessio","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hbpd.2024.11.004_bib0023","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1158\/1078-0432.CCR-22-0025","article-title":"Neoadjuvant approaches in hepatocellular carcinoma: there's no time like the present","volume":"28","author":"Franses","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hbpd.2024.11.004_bib0024","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/hep.31697","article-title":"Perspectives on the neoadjuvant use of immunotherapy in hepatocellular carcinoma","volume":"74","author":"Pinato","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.hbpd.2024.11.004_bib0025","doi-asserted-by":"crossref","first-page":"3508","DOI":"10.3390\/cancers15133508","article-title":"Systemic neoadjuvant and adjuvant therapies in the management of hepatocellular carcinoma-a narrative review","volume":"15","author":"Chamseddine","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.hbpd.2024.11.004_bib0026","doi-asserted-by":"crossref","first-page":"600","DOI":"10.3390\/cancers15030600","article-title":"Neoadjuvant immune checkpoint inhibitors for resectable hepatocellular carcinoma: a systematic review and meta-analysis","volume":"15","author":"Zhao","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.hbpd.2024.11.004_bib0027","article-title":"Surgery after conversion therapy with PD-1 inhibitors plus tyrosine kinase inhibitors are effective and safe for advanced hepatocellular carcinoma: a pilot study of ten patients","volume":"11","author":"Zhang","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.hbpd.2024.11.004_bib0028","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.2147\/JHC.S432062","article-title":"Hepatectomy after conversion therapy with hepatic arterial infusion chemotherapy, tyrosine kinase inhibitors and anti-PD-1 antibodies for initially unresectable hepatocellular carcinoma","volume":"10","author":"Yu","year":"2023","journal-title":"J Hepatocell Carcinoma"},{"key":"10.1016\/j.hbpd.2024.11.004_bib0029","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007366","article-title":"Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial","volume":"11","author":"Zhang","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.hbpd.2024.11.004_bib0030","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.hbpd.2022.08.002","article-title":"Biomarkers for response to immunotherapy in hepatobiliary malignancies","volume":"21","author":"Lin","year":"2022","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"10.1016\/j.hbpd.2024.11.004_bib0031","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1148\/radiol.2020192797","article-title":"Diagnostic performance of LI-RADS treatment response algorithm for hepatocellular carcinoma: adding ancillary features to MRI compared with enhancement patterns at CT and MRI","volume":"296","author":"Park","year":"2020","journal-title":"Radiology"},{"key":"10.1016\/j.hbpd.2024.11.004_bib0032","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jhep.2019.09.026","article-title":"mRECIST for HCC: performance and novel refinements","volume":"72","author":"Llovet","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.hbpd.2024.11.004_bib0033","doi-asserted-by":"crossref","first-page":"929","DOI":"10.2147\/JHC.S357313","article-title":"Neoadjuvant therapy for hepatocellular carcinoma","volume":"9","author":"Yin","year":"2022","journal-title":"J Hepatocell Carcinoma"},{"key":"10.1016\/j.hbpd.2024.11.004_bib0034","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.3390\/cancers15051538","article-title":"MVI-TR: a transformer-based deep learning model with contrast-enhanced CT for preoperative prediction of microvascular invasion in hepatocellular carcinoma","volume":"15","author":"Cao","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.hbpd.2024.11.004_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2023.107786","article-title":"Deep learning nomogram for preoperative distinction between Xanthogranulomatous cholecystitis and gallbladder carcinoma: a novel approach for surgical decision","volume":"168","author":"Zhang","year":"2024","journal-title":"Comput Biol Med"},{"key":"10.1016\/j.hbpd.2024.11.004_bib0036","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2022.872044","article-title":"Pretreatment computed tomography-based machine learning models to predict outcomes in hepatocellular carcinoma patients who received combined treatment of trans-arterial chemoembolization and tyrosine kinase inhibitor","volume":"10","author":"Ren","year":"2022","journal-title":"Front Bioeng Biotechnol"},{"key":"10.1016\/j.hbpd.2024.11.004_bib0037","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1159\/000528034","article-title":"Tumor radiomic features on pretreatment MRI to predict response to lenvatinib plus an anti-PD-1 antibody in advanced hepatocellular carcinoma: a multicenter study","volume":"12","author":"Xu","year":"2022","journal-title":"Liver Cancer"}],"container-title":["Hepatobiliary & Pancreatic Diseases International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1499387224001590?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1499387224001590?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T20:10:05Z","timestamp":1742328605000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1499387224001590"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S1499387224001590"],"URL":"https:\/\/doi.org\/10.1016\/j.hbpd.2024.11.004","relation":{},"ISSN":["1499-3872"],"issn-type":[{"value":"1499-3872","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic chemotherapy improves outcome of hepatocellular carcinoma patients treated with transarterial chemoembolization","name":"articletitle","label":"Article Title"},{"value":"Hepatobiliary & Pancreatic Diseases International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hbpd.2024.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 First Affiliated Hospital, Zhejiang University School of Medicine in China. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}